
Chinese General Practice ›› 2018, Vol. 21 ›› Issue (27): 3397-3402.DOI: 10.3969/j.issn.1007-9572.2018.00.232
Special Issue: 消化系统疾病最新文章合辑
• Monographic Research • Previous Articles Next Articles
Published:2018-09-20
Online:2018-09-20
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.3969/j.issn.1007-9572.2018.00.232
| [1]BROWNING J D,SZCZEPANIAK L S,DOBBINS R,et al.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J].Hepatology,2004,40(6):1387-1395.DOI:10.1002/hep.20466.3400 [2]VERNON G,BARANOVA A,YOUNOSSI Z M.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.DOI:10.1111/j.1365-2036.2011.04724.x.3400 [3]CLEMENTE M G,MANDATO C,POETA M,et al.Pediatric non-alcoholic fatty liver disease:recent solutions,unresolved issues,and future research directions[J].World J Gastroenterol,2016,22(36):8078-8093.DOI:10.3748/wjg.v22.i36.8078.3401 [4]LU Z Y,SHAO Z,LI Y L,et al.Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population:an 8-year follow-up study[J].World J Gastroenterol,2016,22(13):3663-3669.3401 [5]CHALASANI N,YOUNOSSI Z,LAVINE J E,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology[J].Gastroenterology,2012,142(7):1592-1609.DOI:10.1053/j.gastro.2012.04.001.3401 [6]WONG R J,CHEUNG R,AHMED A.Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.[J].Hepatology,2014,59(6):2188-2195.DOI:10.1002/hep.26986.3401 [7]KUSHIYAMA A,NAKATSU Y,MATSUNAGA Y,et al.Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis[J].Mediators Inflamm,2016,2016:8603164.DOI:10.1155/2016/8603164.3401 [8]SHARAF EL DIN UAA,SALEM M M,ABDULAZIM D O.Uric acid in the pathogenesis of metabolic,renal,and cardiovascular diseases:a review[J].J Adv Res,2017,8(5):537-548.DOI:10.1016/j.jare.2016.11.004.3401 [9]MAIUOLO J,OPPEDISANO F,GRATTERI S,et al.Regulation of uric acid metabolism and excretion[J].Int J Cardiol,2016,213:8-14.DOI:10.1016/j.ijcard.2015.08.109.3401 [10]KAMOGAWA E,SUEISHI Y.A multiple free-radical scavenging(MULTIS)study on the antioxidant capacity of a neuroprotective drug,edaravone as compared with uric acid,glutathione,and trolox[J].Bioorg Med Chem Lett,2014,24(5):1376-1379.DOI:10.1016/j.bmcl.2014.01.045.3401 [11]ASHTARI F,BAHAR M,AGHAEI M,et al.Serum uric acid level in patients with relapsing-remitting multiple sclerosis[J].J Clin Neurosci,2013,20(5):676-678.DOI:10.1016/j.jocn.2012.05.054.3401 [12]SAUTIN Y Y,NAKAGAWA T,ZHARIKOV S,et al.Adverse effects of the classic antioxidant uric acid in adipocytes:NADPH oxidase-mediated oxidative/nitrosative stress[J].Am J Physiol Cell Physiol,2007,293(2):C584-596.DOI:10.1152/ajpcell.00600.2006.3401 [13]MARTYN K D,FREDERICK L M,VON LOEHNEYSEN K,et al.Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases[J].Cell Signal,2006,18(1):69-82.DOI:10.1016/j.cellsig.2005.03.023.3401 [14]张涛,迟雁青,杜春阳,等.尿酸对人肾小管上皮细胞氧化应激和TGF-β表达的影响[J].免疫学杂志,2014,30(7):585-589.DOI:10.13431/j.cnki.immunol.j.20140128.3401 ZHANG T,CHI Y Q,DU C Y,et al.Effects of uric acid on oxidative stress and TGF-β expression of human renal tubular epithelia cell[J].Immunological Journal,2014,30(7):585-589.DOI:10.13431/j.cnki.immunol.j.20140128.3401 [15]LIU C Q,HE C M,CHEN N,et al.Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults[J].Sci Rep,2016,6:38605.DOI:10.1038/srep38605.3401 [16]LIN H,LI Q,LIU X,et al.Liver fat content is associated with elevated serum uric acid in the Chinese middle-aged and elderly populations:Shanghai Changfeng Study[J].PLoS One,2015,10(10):e0140379.DOI:10.1371/journal.pone.0140379.3401 [17]LIU Z,QUE S,ZHOU L,et al.Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence:a meta-analysis of prospective studies[J].Sci Rep,2015,5:14325.DOI:10.1038/srep14325.3401 [18]YU T Y,JEE J H,BAE J C,et al.Serum uric acid:a strong and independent predictor of metabolic syndrome after adjusting for body composition[J].Metabolism,2016,65(4):432-440.DOI:10.1016/j.metabol.2015.11.003.3401 [19]CAI W,SONG J M,ZHANG B,et al.The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population[J].Scientific World Journal,2014,2014:393628.DOI:10.1155/2014/393628.3401 [20]HUANG Q,YU J,ZHANG X,et al.Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease[J].Biomed Rep,2016,5(2):188-192.DOI:10.3892/br.2016.698.3401 [21]WU S J,ZHU G Q,YE B Z,et al.Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults:a large population-based study[J].Medicine(Baltimore),2015,94(17):e802.DOI:10.1097/MD.0000000000000802.3401 [22]WAN X,XU C,LIN Y,et al.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J].J Hepatol,2016,64(4):925-932.DOI:10.1016/j.jhep.2015.11.022.3401 [23]LOMBARDI R,PISANO G,FARGION S.Role of serum uric acid and ferritin in the development and progression of NAFLD[J].Int J Mol Sci,2016,17(4):548.DOI:10.3390/ijms17040548.3401 [24]LI C,HSIEH M C,CHANG S J.Metabolic syndrome,diabetes,and hyperuricemia[J].Curr Opin Rheumatol,2013,25(2):210-216.DOI:10.1097/BOR.0b013e32835d951e.3401 [25]VACCA M,ALLISON M,GRIFFIN J L,et al.Fatty acid and glucose sensors in hepatic lipid metabolism:implications in NAFLD[J].Semin Liver Dis,2015,35(3):250-261.DOI:10.1055/s-0035-1562945.3401 [26]ZHI L,YUZHANG Z,TIANLIANG H,et al.High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo[J].PLoS One,2016,11(2):e0147737.DOI:10.1371/journal.pone.0147737.3401 [40]GOPAL K,JOHNSON T C,GOPAL S,et al.Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment[J].Hepatology,2006,44(2):335-340.DOI:10.1002/hep.21261.3402 [41]GIRELLI D,PASINO M,GOODNOUGH J B,et al.Reduced serum hepcidin levels in patients with chronic hepatitis C[J].J Hepatol,2009,51(5):845-852.DOI:10.1016/j.jhep.2009.06.027.3402 [42]GOPAL K,JOHNSON T C,GOPAL S,et al.Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment[J].Hepatology,2006,44(2):335-340.DOI:10.1002/hep.21261.3402 [43]BODLAJ G,HUBMANN R,SALEH K,et al.Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response[J].World J Gastroenterol,2010,16(19):2407-2410.DOI:10.3748/wjg.v16.i19.2407.3402 [44]EZZIKOURI S,KIMURA K,SUNAGOZAKA H,et al.Serum DHCR24 auto-antibody as a new biomarker for progression of hepatitis C[J].EBioMedicine,2015,2(6):604-612.DOI:10.1016/j.ebiom.2015.04.007.3402 [45]SAITO M,YANO Y,HIRANO H,et al.Serum NX-DCP as a new noninvasive model to predict significant liver fibrosis in chronic hepatitis C[J].Hepat Mon,2015,15(2):e22978.DOI:10.5812/hepatmon.22978.3402 [27]AVULA N R,SHENOY D.Evaluation of association of hyperuricaemia with metabolic syndrome and insulin resistance[J].J Clin Diagn Res,2016,10(12):OC32-34.DOI:10.7860/JCDR/2016/22182.9113.3402 [28]TAKIR M,KOSTEK O,OZKOK A,et al.Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia[J].J Investig Med,2015,63(8):924-929.DOI:10.1097/JIM.0000000000000242.3402 [29]LANASPA M A,SANCHEZ-LOZADA L G,CHOI Y J,et al.Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress:potential role in fructose-dependent and -independent fatty liver[J].J Biol Chem,2012,287(48):40732-40744.DOI:10.1074/jbc.M112.399899.3402 [30]CHOI Y J,SHIN H S,CHOI H S,et al.Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes[J].Lab Invest,2014,94(10):1114-1125.DOI:10.1038/labinvest.2014.98.3402 [31]SOZEN E,OZER N K.Impact of high cholesterol and endoplasmic reticulum stress on metabolic diseases:an updated mini-review[J].Redox Biol,2017,12:456-461.DOI:10.1016/j.redox.2017.02.025.3402 [32]DE TORRE-MINGUELA C,MESA DEL CASTILLO P,PELEGRN P.The NLRP3 and pyrin inflammasomes:implications in the pathophysiology of autoinflammatory diseases[J].Front Immunol,2017,8:43.DOI:10.3389/fimmu.2017.00043.3402 [33]CAI C,ZHU X,LI P,et al.NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid[J].Inflammation,2017,40(6):1875-1883.DOI:10.1007/s10753-017-0628-z.3402 [34]WAN X,XU C,LIN Y,et al.Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism[J].J Hepatol,2016,64(4):925-932.DOI:10.1016/j.jhep.2015.11.022.3402 [35]RONCAL-JIMENEZ C A,LANASPA M A,RIVARD C J,et al.Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake[J].Metabolism,2011,60(9):1259-1270.DOI:10.1016/j.metabol.2011.01.008.3402 [36]JOHNSON R J,NAKAGAWA T,SANCHEZ-LOZADA L G,et al.Sugar,uric acid,and the etiology of diabetes and obesity[J].Diabetes,2013,62(10):3307-3315.DOI:10.2337/db12-1814.3402 [37]ISHIMOTO T,LANASPA M A,LE M T,et al.Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice[J].Proc Natl Acad Sci U S A,2012,109(11):4320-4325.DOI:10.1073/pnas.1119908109.3402 [38]LANASPA M A,SANCHEZ-LOZADA L G,CICERCHI C,et al.Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver[J].PLoS One,2012,7(10):e47948.DOI:10.1371/journal.pone.0047948.3402 [39]旷历琼,王娜.中老年非酒精性脂肪肝患者临床特点及其与血脂、血尿酸水平的相关性分析[J].疑难病杂志,2014,13(10):1012-1014.DOI:10.3969/j.issn.1671-6450.2014.10.08.3402 KUANG L Q,WANG N.The characters of nonalcoholic fatty liver disease and the related risk factors with blood lipid and serum uric acid[J].Chinese Journal of Difficult and Complicated Cases,2014,13(10):1012-1014.DOI:10.3969/j.issn.1671-6450.2014.10.08.3402 [40]高锦凤,宋镇,何方平,等.非酒精性脂肪性肝病与尿酸水平和肾功能损伤的相关性研究[J].疑难病杂志,2010,9(7):518-520.DOI:10.3969/j.issn.1671-6450.2010.07.018.3402 GAO J F,SONG Z,HE F P,et al.Relationship between uric acid level and renal function impairment in nonalcoholic fatty liver disease[J].Chinese Journal of Difficult and Complicated Cases,2010,9 (7):518-520.DOI:10.3969/j.issn.1671-6450.2010.07.018.3402 |
| [1] | GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859. |
| [2] | ZHANG Mei, LI Mengqi, LU Shuangyan, PU Huijie, LI Guitao, DIAO Yi, TAO Hui, FAN Luming, YE Aifang, MAO Yong. Association between the Ratio of Uric Acid to High-density Lipoprotein Cholesterol and Metabolic Syndrome in the Yi Ethnic Group of Yunnan Province [J]. Chinese General Practice, 2026, 29(18): 2532-2537. |
| [3] | HUANG Minshan, CHEN Hang, LI Liya, YANG Taiming, CHEN Lifang, LI Shenchao, REN Li, WANG Hui, LI Mingke, WANG Xianmei, WANG Da, WAN Ying, HE Yule, ZHOU Qingqing, LI Yu, LI Mengwei, LU Lihong, LUO Yifan, MA Lanqing. The Current Status of Awareness and Influencing Factors Analysis of Metabolic-associated Fatty Liver Disease among the General Population in Multiple Regions of Yunnan [J]. Chinese General Practice, 2026, 29(17): 2347-2353. |
| [4] | ZHANG Xinwen, WEI Guangcheng, ZHANG Xieyu, SHI Jinjie, LI Xiaoxu, MA Rui, YA Yulong, PENG Jiucheng, CAO Wei. The Causal Relationship between Sleep Patterns and Serum Uric Acid: a Bidirectional Mendelian Randomization Study [J]. Chinese General Practice, 2026, 29(17): 2354-2360. |
| [5] | WU Zhiyuan, WANG Chuanxu, YANG Feng, ZHANG Xuming, ZHOU Jiabao, GAO Jiandong. Study on the Mechanism of Shizhi Fang in Uric Acid Transport-related Proteins in Hyperuricemia [J]. Chinese General Practice, 2026, 29(14): 1898-1910. |
| [6] | LI Jie, YANG Xinhui, CAO Li, ZHANG Jing, JIANG Yue. Case Analysis of General Practice Diagnosis and Treatment in a "Three High" Patient with Coexistence and Fatty Liver Disease [J]. Chinese General Practice, 2026, 29(06): 810-816. |
| [7] | ZHU Chenrui, LI Na, WU Yuntao, ZHAO Haiyan, HUANG Zhe, LIU Yan, JI Chunpeng, WU Shouling. The Impact of Serum Uric Acid Levels on New-onset Atrioventricular Block: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(05): 583-590. |
| [8] | FAN Xueming, YANG Ningning, ZHENG Zheng, WU Yumei, WANG Qi. Analysis of Correlation Factors and Predictive Value of Microvascular Complications in Patients with Type 2 Diabetes Mellitus Combined with Metabolic-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(36): 4578-4585. |
| [9] | YANG Bingqing, YANG Tianyuan, HOU Chenxue, WANG Qi. Comparative Study on the Potential of Non-invasive Models in Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Combined with Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(32): 4067-4074. |
| [10] | YANG Jian, WU Chuan'an, ZHOU Hairong, TIAN Feng, CHI Chunhua. Diagnostic Value of the Triglyceride Glucose-body Mass Index for Type 2 Diabetes Mellitus Combined with Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(32): 4075-4081. |
| [11] | ZHAO Yuqing, WANG Wei, CHEN Liyuan, YOU Huijuan, WEI Ying, WANG Qinglu, YANG Fengying. Liver Macrophage Polarisation: a New Target for Exercise Prevention and Treatment of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(27): 3456-3465. |
| [12] | WU Sha, ZHANG Daiyi, LI Jin, XUAN Qinkao, QIAN Xiaodong, ZHU Chuanwu, PU Jianhong, ZHU Li. Correlation Analysis and Model Construction of Metabolic Associated Fatty Liver Disease and Hyperglycemia Based on a Health Examination Cohort [J]. Chinese General Practice, 2025, 28(23): 2861-2869. |
| [13] | LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860. |
| [14] | WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851. |
| [15] | BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||